<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959903</url>
  </required_header>
  <id_info>
    <org_study_id>SI101-01</org_study_id>
    <nct_id>NCT04959903</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT</brief_title>
  <official_title>A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smart Immune SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smart Immune SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T&#xD;
      Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell&#xD;
      depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric&#xD;
      patients with relapsed/refractory acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of grade III-IV GvHD</measure>
    <time_frame>100 days post-HSCT</time_frame>
    <description>to evaluate the safety profile of the study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events related to SMART101</measure>
    <time_frame>100 days post-HSCT</time_frame>
    <description>Number of adverse events and serious adverse events related to SMART101 tabulated for each dose and by age group to evaluate the safety profile of the study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ T cell count</measure>
    <time_frame>100 days post-HSCT</time_frame>
    <description>to evaluate the efficacy of the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell immune reconstitution</measure>
    <time_frame>up to Month 12 post-HSCT</time_frame>
    <description>Time course of the T cell immune reconstitution, with a focus on naive CD4+ cells and total CD8+ cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of infections</measure>
    <time_frame>Day 90, and Months 6, 12 and 24 post-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 90, and Months 6, 12 and 24 post-HSCT</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Month 24 post-HSCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Month 24 post-HSCT</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Adult patients affected by acute leukemia (AML, ALL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric patients affected by acute leukemia (AML, ALL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic T cell progenitors, cultured ex-vivo</intervention_name>
    <description>Injection of T cell progenitors at [Day 4-Day 10] after T cell depleted allogeneic HSCT</description>
    <arm_group_label>Adult patients affected by acute leukemia (AML, ALL)</arm_group_label>
    <arm_group_label>Pediatric patients affected by acute leukemia (AML, ALL)</arm_group_label>
    <other_name>SMART101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group A (adults):&#xD;
&#xD;
          1. Adult patients affected by acute leukemia (AML, ALL) defined as:&#xD;
&#xD;
               -  Acute Myeloid Leukemia (AML):&#xD;
&#xD;
                    -  High risk AML in CR1; any adverse genetic abnormality, secondary or therapy&#xD;
                       related AML excluding good risk genetic abnormalities&#xD;
&#xD;
                    -  Chemo-refractory relapse (MRD+)&#xD;
&#xD;
                    -  ≥ CR2&#xD;
&#xD;
               -  Acute Lymphoblastic Leukemia (ALL):&#xD;
&#xD;
                    -  Chemo-refractory relapse (MRD+)&#xD;
&#xD;
                    -  High risk in CR1; Philadelphia (like) or any poor risk feature&#xD;
&#xD;
                    -  ≥ CR2&#xD;
&#xD;
          2. Patient eligible for an allogeneic HSCT&#xD;
&#xD;
          3. Age ≥ 21y and clinical condition compatible with allogeneic bone marrow&#xD;
             transplantation&#xD;
&#xD;
          4. Karnofsky index ≥ 70%&#xD;
&#xD;
          5. Patients with normal organ function&#xD;
&#xD;
        Group B (pediatrics):&#xD;
&#xD;
          1. Pediatric patients affected by acute leukemia (AML, ALL) defined as:&#xD;
&#xD;
               -  Acute Myeloid Leukemia (AML):&#xD;
&#xD;
                    -  High risk AML in CR1; any adverse genetic abnormality, secondary or therapy&#xD;
                       related AML excluding good risk genetic abnormalities,&#xD;
&#xD;
                    -  Chemo-refractory relapse (MRD+)&#xD;
&#xD;
                    -  ≥ CR2&#xD;
&#xD;
               -  Acute Lymphoblastic Leukemia (ALL):&#xD;
&#xD;
                    -  Chemo-refractory relapse (MRD+)&#xD;
&#xD;
                    -  High risk in CR1; Philadelphia (like) or any poor risk feature&#xD;
&#xD;
                    -  ≥ CR2&#xD;
&#xD;
          2. Patient eligible for an allogeneic HSCT&#xD;
&#xD;
          3. Age &lt; 21y at the time of inclusion&#xD;
&#xD;
          4. Absence of a matched sibling donor (MSD)&#xD;
&#xD;
          5. Lansky ≥ 70% / Karnofsky ≥ 70%&#xD;
&#xD;
          6. Patients with normal organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Groups A and B:&#xD;
&#xD;
          1. Planned use of an HLA matched CB (8/8 allele matched).&#xD;
&#xD;
          2. Prior therapy with allogeneic stem cell transplantation&#xD;
&#xD;
          3. Treatment with another cellular therapy within one month before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaap-Jan BOELENS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center (MSKCC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD, PhD</last_name>
    <phone>+33 1 88 33 82 59</phone>
    <email>marina.cavazzana@smart-immune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura SIMONS, MD, PhD</last_name>
    <email>laura.simons@smart-immune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (MSKCC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jaap-Jan BOELENS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel-Angel PERALES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

